This observation—coupled with the positive correlation between LSD1 and GSK3β immunohistochemical expression in human cancer specimens—may prompt further preclinical studies on the combined used of LSD1 and GSK3β inhibitors. The gene discussed is GSK3B; the disease is cancer.